SCHEMBL3232247

SCHEMBL3232247

CN1CCN(c2ccc(F)cc2)c2ccc(-c3ncccn3)cc2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.48
HRH4 Q9H3N8 1/20 0.40
MAPKAPK2 P49137 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HTR1A P08908 1/20 0.36
DRD4 P21917 1/20 0.36
HTR1B P28222 1/20 0.36
DRD3 P35462 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
EGFR P00533 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CCNA1 P78396 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479538 0.91 SCN9A (0.43) SCN9AHRH4MAPKAPK2L3MBTL1ALDH1A1
SCHEMBL3230914 0.89 SCN9A (0.45) SCN9AHRH4MAPKAPK2L3MBTL1RAB9A
SCHEMBL3479576 0.88 SCN9A (0.44) SCN9AL3MBTL1ALDH1A1RAB9A
SCHEMBL3233371 0.88 SCN9A (0.44) SCN9AHRH4L3MBTL1ALDH1A1DRD3
SCHEMBL3479700 0.88 SCN9A (0.46) SCN9AHRH4MAPKAPK2LMNASMN1; SMN2
SCHEMBL3224959 0.87 SCN9A (0.52) SCN9AHRH4MAPKAPK2ALDH1A1NPC1
SCHEMBL3479628 0.84 SCN9A (0.48) SCN9AHRH4MAPKAPK2DRD2
SCHEMBL3479598 0.84 HTR3A (0.46) SCN9AHRH4L3MBTL1HTR1ADRD3
SCHEMBL3479963 0.84 HRH4 (0.44) SCN9AHRH4DRD3DRD2
SCHEMBL3234679 0.83 SCN9A (0.39) SCN9AHRH4ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885HRH4 90/4885MAPKAPK2 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.